Bristol Myers Squibb's Abecma (idecabtagene vicleucel) becomes the first CAR T cell therapy approved in the European Union in prior lines for relapsed and refractory triple-class exposed multiple myeloma.

Abecma demonstrated superiority over standard treatment regimens in the phase 3 KarMMa-3 trial, with a 51% reduction in the risk of disease progression or death, and a well-established safety profile, with mainly transient and low-grade occurrences of cytokine release syndrome and neurotoxicity.

' 'Today's approval in the European Union marks an important milestone in our efforts to bring the transformative potential of cell-based therapies to the front lines of treatment,' said Monica Shaw, M.D., senior vice president and head of European markets at Bristol Myers Squibb.

' Abecma is an important treatment option for patients with relapsed and refractory triple class multiple myeloma who have received at least two prior therapies, and paves the way for a promising shift in the treatment paradigm. '

Copyright (c) 2024 CercleFinance.com. All rights reserved.